Eli Lilly announced clinical trial results this week for a daily pill to treat obesity and diabetes. Its name is absolutely ...

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...

Novo Nordisk (NVO) announced on Friday that it has secured a legal victory against compounders selling unauthorized versions ...

Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug ...

Novo Nordisk sees roughly 57% of its sales from the US pharmaceutical market, giving it significant exposure to US policy changes. Novo’s portfolio has high exposure to Medicare, and the firm ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand ... which marks one of the largest ever for pharmaceuticals in Brazil, will “significantly ...

Novo Nordisk will pay $75 million in up-front and near-term payments for Lexicon Pharmaceuticals’ LX9851, a small molecule the firm says it is developing for obesity and associated metabolic ...

Novo Nordisk employs about 76,300 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen Facebook , Instagram , X ...

Bagsværd, Denmark, 3 April 2025 – Novo Nordisk today announced the following changes ... PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest ...

Lexicon Pharmaceuticals focuses on the development of medicines ... performance coincides with Lexicon’s announcement of a major licensing agreement with Novo Nordisk for the development and ...

In this week’s edition of InnovationRx, we look at Trump's massive health agency layoffs, Palantir’s trade secret lawsuit, Gather Health’s new primary care model, Airna’s $155 million deal, and more.